

NOTICE

in relation to the Final Terms of

**MAX LONG CERTIFICATES on SOLACTIVE US PHARMA 10% RISK CONTROL 3%
DECREMENT NET (EUR) Index due 02.12.2027**

commercial name: Equity Protection su Indice US Pharma - SOLUSPH3 Index

ISIN Code: XS2243733925

(respectively, the "Final Terms" and the "Certificates")

**to be issued under the Warrants and Certificates Programme IMI CIB dated 12 June 2020 approved by
the Commission de Surveillance du Secteur Financier (CSSF) in its capacity as competent authority of
Luxembourg (the "Base Prospectus"), as amended by the relevant supplement**

In relation to the Final Terms published by the Issuer on 9 October 2020, the Issuer hereby gives notice of the increase of the maximum amount of Certificates offered from EUR 100,000,000 (100,000 Certificates) to EUR 110,000,000 (110,000 Certificates).

For this reason, the Issuer has also published the amended and restated Final Terms dated 17 November 2020.

Terms used herein and not otherwise defined shall have the same meaning ascribed to them in the Final Terms relating to the Certificates.

Milan, 17 November 2020

Intesa Sanpaolo S.p.A.